SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

PRAX-110

PRAX·Praxis Precision Medicines, Inc.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Not stated
Time to market
Not stated
Why 4/10
No upcoming catalyst for PRAX-110 could be identified; the drug does not appear in any public pipeline, clinical trial database, FDA catalyst list, or press release for Praxis Precision Medicines. The company's next hard catalysts are the PDUFA dates for relutrigine (Dec 27, 2026) and ulixacaltamide (Jan 29, 2027), but these are different drugs.
Actionable Insight NEUTRAL

PRAX-110 is not a recognized pipeline asset of Praxis Precision Medicines based on available public data. Investors should monitor the company's official pipeline disclosures for any mention of this candidate. The stock's near-term value is driven by the relutrigine PDUFA on December 27, 2026 and the ulixacaltamide PDUFA on January 29, 2027.

Price Chart

Loading chart...

Executive Summary

PRAX-110 is not a publicly documented drug candidate from Praxis Precision Medicines. Extensive web searches, SEC filings, FDA catalyst databases, clinical trial registries, and press releases failed to return any mention of PRAX-110 as a pipeline asset. The company's known pipeline includes relutrigine (PRAX-562), ulixacaltamide, elsunersen, and PRAX-628. Without any verifiable data on PRAX-110's mechanism, indication, or clinical status, no informed investment thesis can be constructed for this specific molecule.

The Two-Sided Case

▲ Bull Case1
No evidence of PRAX-110 exists in public sources, so no bull case can be constructed.
▼ Bear Case3
PRAX-110 does not appear in any of Praxis Precision Medicines' public pipeline disclosures, SEC filings, press releases, or clinical trial registries as of November 2026.
The name may be a typo, an abandoned early-stage program, or an internal code that was never publicly disclosed.
If PRAX-110 is a real but undisclosed asset, its non-appearance in any pipeline update suggests it is likely preclinical or discontinued.

Upcoming Catalysts

  • No catalysts identified for PRAX-110. For the company overall: relutrigine PDUFA on December 27, 2026; ulixacaltamide PDUFA on January 29, 2027; EMERALD study topline results expected Q4 2026.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Praxis Precision Medicines, Inc. 8-K PRAX ·Originating report

Sources · 2

Hover a chip for the title
1 markets.businessinsider.com2 marketscreener.com